real-time news and commentary for investors
Thursday, Oct 31
ViroPharma lifts Cinryze guidance, shares rise
- ViroPharma (VPHM +4.8%) is enjoying a strong session on the back of its Q3 results.
- U.S. Cinryze sales come in at $102M for the period — that's up 12% sequentially and 21% Y/Y. Inventory levels were unchanged.
- FY13 outlook: Net product sales of $445-465M, North American Cinryze sales of $395-405M (versus previous guidance of $390-400M), and R&D spend of $240-260M (unchanged).